Acute Corticotropin-Releasing Factor Receptor Type 2 Agonism Results in Sustained Symptom Improvement in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.
Pereira, Gerard, Gillies, Hunter, Chanda, Sanjay et al. · Frontiers in systems neuroscience · 2021 · DOI
Quick Summary
Researchers tested a new drug called CT38s that targets a receptor in the brain called CRFR2, which they believe may be overactive in ME/CFS. Fourteen ME/CFS patients received a single infusion of this drug, and most experienced symptom improvement that lasted at least 28 days. Side effects were mild and similar to typical ME/CFS symptoms, suggesting the drug was working on systems related to the disease.
Why It Matters
This study provides preliminary evidence for a specific biological mechanism in ME/CFS (CRFR2 upregulation) and demonstrates that targeting this mechanism with a single drug dose may produce meaningful, sustained symptom improvement. These findings could redirect ME/CFS research toward a mechanistically-informed treatment approach and justify larger controlled trials.
Observed Findings
At 0.03 μg/kg/h infusion rate, mean TDSS improved by −7.5 ± 1.9 points (−25.7%, p = 0.009) and remained improved over 28 days post-infusion
All 13 monitored individual symptoms showed improvement at the optimal dose
ME/CFS patients demonstrated greater sensitivity to hemodynamic effects of CRFR2 stimulation compared to healthy controls in prior studies
Adverse events were generally mild, resolved without intervention, and difficult to distinguish from baseline ME/CFS symptoms
Symptom improvement correlated with both total drug exposure and pre-treatment symptom severity
Inferred Conclusions
CRFR2 is likely upregulated in ME/CFS based on enhanced hemodynamic sensitivity and the symptom profile of acute CRFR2 stimulation
Acute CRFR2 agonism-induced receptor downregulation may represent a viable therapeutic mechanism warranting further investigation
A single acute dose of CT38s can produce sustained multi-symptom improvement lasting at least 28 days
The observed safety profile supports continued development of CRFR2-targeted therapies in ME/CFS
Remaining Questions
Does the observed symptom improvement persist beyond 28 days, and what is the durability of benefit over months or years?
What This Study Does Not Prove
This study does not prove CT38s is an effective treatment for ME/CFS, as it lacks a control group and relies on patient self-reported symptoms in an open-label design susceptible to placebo effects. It does not establish that CRFR2 upregulation is the sole or primary cause of ME/CFS, only that it may play a role in symptom generation. Results in 14 patients cannot be generalized to the broader ME/CFS population without larger controlled trials.